← All trials
NCT06672822
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- May 31, 2025
- Completion date
- Nov 30, 2025
- First posted
- Nov 4, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghSponsor investigator
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- University of PittsburghOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.